OPKO Health, Inc. (OPK)

Market Cap	830.60M -12.9%
Revenue (ttm)	581.12M -15.7%
Net Income	-212.92M
EPS	-0.28
Shares Out	755.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,962,706
Open	1.130
Previous Close	1.125
Day's Range	1.100 - 1.140
52-Week Range	0.977 - 1.600
Beta	1.41
Analysts	Hold
Price Target	1.60 (+45.46%)
Earnings Date	Apr 28, 2026

About OPK

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 2, 1995
• Employees: 2,275
• Stock Exchange: NASDAQ
• Ticker Symbol: OPK
• Website: https://www.opko.com

Financial Performance

In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for OPK stock is "Hold." The 12-month stock price target is $1.6, which is an increase of 45.46% from the latest price.

Price Target

$1.6

(45.46% upside)

Analyst Consensus: Hold